US4046878A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Daunomycin analogues, their preparation and use
Assignee: Pfizer Italia SRL
•
Filing: 1975-05-22
•
Granted: 1977-09-06
•
Expires: 1995-05-22
Abstract
Abstract Daunomycin analogues of the formula: ##STR1## wherein when each R 1 is hydrogen, each R is hydrogen, chlorine, bromine, methyl or methoxy and when each R 1 is chlorine, bromine or methyl, each R is hydrogen, are useful in treating various mammalian tumors and are prepared by reacting a daunomycinone derivative of the formula: ##STR2## wherein R and R 1 are as defined above with 1-chloro-2,3,6-trideoxy-3-trifluoroacetamido-4-trifluoroacetoxy-α-L-lyxopyranose in an inert anhydrous organic solvent in the presence of a catalyst and a hydrogen chloride acceptor.
Inventors
- 👤 Bianca Patelli
- 👤 Luigi Bernardi
- 👤 Federico Arcamone
- 👤 Aurelio Di Marco
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-24 01:14
CPC Classifications
C; C07; C07H; C07H15/00; C07H15/20; C07H15/24; C07H15/252
Claims Analysis
Total Claims: 21
Claim 1
Independent Claim
50 words
A racemic daunomycin analogue of the formula ##STR5## comprising the α-anomer, the β-anomer or a mixture of α- and β-anomers wherein when each R 1 is hydrogen, each R is hydrogen, chlorine, bromine methyl or methoxy; and when each R 1 is chlorine, bromine or methyl, each R is hydrogen.
Claim 2
Dependent Claim
50 words
A racemic daunomycin analogue of the formula ##STR5## comprising the α-anomer, the β-anomer or a mixture of α- and β-anomers wherein when each R 1 is hydrogen, each R is hydrogen, chlorine, bromine methyl or methoxy; and when each R 1 is chlorine, bromine or methyl, each R is hydrogen.
Claim 3
Dependent Claim
13 words
A compound according to claim 1, which is (-)daunosaminyl (-)1,4-dimethyl-4-demethoxydaunomycinone (α- and β-anomers).
Claim 4
Dependent Claim
13 words
A compound according to claim 1, which is (-)daunosaminyl (+)1,4-dimethyl-4-demethoxydaunomycinone (α- and β-anomers).
Claim 5
Dependent Claim
13 words
A compound according to claim 1, which is (-)daunosaminyl (-)1-methoxydaunomycinone (α- and β-anomers).
Claim 6
Dependent Claim
12 words
A compound according to claim 1, which is (-)daunosaminyl(+)1-methoxydaunomycinone (α- and β-anomers).
Claim 7
Dependent Claim
12 words
A compound according to claim 1, which is (-)daunosaminyl(-)1,4-dichloro-4-demethoxydaunomycinone (α- and β-anomers).
Claim 8
Dependent Claim
13 words
A compound according to claim 1, which is (-)daunosaminyl (+)1,4-dichloro-4-demethoxydaunomycinone (α- and β-anomers).
Claim 9
Dependent Claim
13 words
A compound according to claim 1, which is (-)daunosaminyl (-)1,4-dibromo-4-demethoxydaunomycinone (α- and β-anomers).
Claim 10
Dependent Claim
13 words
A compound according to claim 1, which is (-)daunosaminyl (+)1,4-dibromo-4-demethoxydaunomycinone (α- and β-anomers).
Claim 11
Dependent Claim
13 words
A compound according to claim 1, which is (-)daunosaminyl(- )2,3-dimethyl-4-demethoxydaunomycinone (α- and β-anomers).
Claim 12
Dependent Claim
12 words
A compound according to claim 1, which is (-)daunosaminyl(+)2,3-dimethyl-4-demethoxydaunomycinone (α- and β-anomers).
Claim 13
Dependent Claim
13 words
A compound according to claim 1, which is (-)daunosaminyl(- )2,3-dichloro-4-demethoxydaunomycinone (α- and β-anomers).
Claim 14
Dependent Claim
13 words
A compound according to claim 1, which is (-)daunosaminyl(+ )2,3-dichloro-4-demethoxydaunomycinone (α- and β-anomers).
Claim 15
Dependent Claim
13 words
A compound according to claim 1, which is (-)daunosaminyl(- )2,3-dibromo-4-demethoxydaunomycinone (α- and β-anomers).
Claim 16
Dependent Claim
12 words
A compound according to claim 1, which is (-)daunosaminyl(+)2,3-dibromo-4-demethoxydaunomycinone (α- and β-anomers).
Claim 17
Dependent Claim
12 words
A compound according to claim 1, which is (-)daunosaminyl(-)4-demethoxydaunomycinone (α- and β-anomers).
Claim 18
Dependent Claim
12 words
A compound according to claim 1, which is (-)daunosaminyl(+)4-demethoxydaunomycinone (α- and β-anomers).
Claim 19
Dependent Claim
59 words
A method of inhibiting the growth of a tumor selected from the group consisting of Moloney Sarcoma Virus, Sarcoma 180 Ascites and L 1210 leukemia which comprises administering to a host afflicted with said tumor an amount of a compound according to claim 1 sufficient to inhibit the growth of said tumor, together with an inert pharmaceutically acceptable carrier.
Claim 20
Dependent Claim
12 words
A method according to claim 18, wherein the compound is administered intravenously.
Claim 21
Dependent Claim
19 words
A method according to claim 18, wherein said compound is a mixture of the α-anomers of (-)daunosaminyl(-)4-demethoxydaunomycinone and (-)daunosaminyl(+)4-demethoxydaunomycinone.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1980-09-05 | 1981-03-07 | 1981-09-06 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1984-09-05 | 1985-03-07 | 1985-09-06 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1988-09-05 | 1989-03-07 | 1989-09-06 | $7700.00 | Window Closed / Lapsed |